Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Scientists Genetically Engineer Patients’ Own Cells to Attack Cancer

December 11, 2015 By Wellcome Trust

In a pioneering trial taking place in London, doctors are harnessing patients’ own immune systems in an effort to find a new effective treatment for resistant head and neck cancer.

The trial of the novel therapy, which involves genetically engineering the patient’s white blood cells so that they recognize and attack the tumor, is taking place at the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at Guy’s and St Thomas’ and King’s College London, with funding from the Wellcome Trust and the J P Moulton Charitable Foundation.

Dr. John Maher, Principal Investigator at the BRC, says: “In most cancers, metastasis, the spread of a disease from the part of the body where it started to another not directly connected, is the commonest cause of death. However, head and neck cancer is unusual in that local spread or recurrence of the disease accounts for most suffering and death. This means that tumors may become inoperable and do not shrink in response to traditional treatments such as chemotherapy or radiotherapy.”

White blood cells of the immune system are naturally equipped to eliminate cells that shouldn’t be there, especially infected cells. However, they sometimes need help to recognize and attack cancer cells. Using a blood sample, Dr. Maher’s team are genetically engineering the patients’ own white blood cells by treating them in the laboratory with a harmless virus that introduces two new genes. The first gene makes it easier to grow the cells during their time in the laboratory while the second enables these white blood cells to recognize and attack the tumor. The resulting treatment is called a CAR T-cell and takes two weeks to produce.

To maximize the safety and effectiveness of this new form of treatment, they are injecting the CAR T-cells directly into the tumor. CAR T-cell treatment has proven very effective in some forms of leukemia but needs to be tested and developed further to benefit patients with solid cancers, such as head and neck cancer.

The main goal of the trial is to test the safety and effectiveness of this new treatment. Patients have been enrolled in groups of three and, if significant side effects are not seen, successive groups will receive a higher number of cells to establish safe dosage.

So far the team has completed the first cohort of three patients in this ongoing trial.

Dr. Maher adds: “If this trial is successful, it could have significant implications for other solid cancers, especially those that spread within a natural space in the body, such as ovarian cancer (lining of the abdomen) or mesothelioma (lining of the lungs). In that setting, it may be possible to inject the CAR T-cells from the patient directly into the cavity, to localize the treatment where it is needed most.”

Life Sciences Minister George Freeman MP said: “This world first trial is an illustration of the value of our £1bn per annum National Institute for Health Research, which pioneers and tests new treatments for the benefits of patients and the NHS. Through our Accelerated Access Review, we intend to fast track breakthroughs like this.”

Dr. Stephen Caddick, Director of Innovations at the Wellcome Trust, said: “Immunotherapy is a very exciting new approach to treating cancer, which takes advantage of the body’s own immune system to tackle the disease. By precision engineering immune cells to recognize and destroy tumors, researchers are hopeful that they will be able to improve the prospects for patients who have, until now, faced very limited treatment options.”

“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe